Also, worth investigating is whether USP19 inhibitors are promising drugs against tumors in general, or only some specific types of tumors, like liver cancers with p53 deletions/mutations that originate in a NAFLD background. This evidence concerns the gene TP53 and metabolic dysfunction-associated steatotic liver disease.